In 2022, Frank Fan moved more than 800 miles from Nan­jing to Shen­zhen, Chi­na, seek­ing a fresh start. He had abrupt­ly left Leg­end Biotech, the CAR-T...

One of Chi­na’s most pro­lif­ic gene edit­ing com­pa­nies has raised its biggest round of fund­ing yet, ahead of plans to go pub­lic in Hong Kong...

👀 ICON’s au­dit probe is com­plete: The in­ves­ti­ga­tion found that ICON’s rev­enue was over­stat­ed by $65.3 mil­lion in 2023 (about 0.8% of its to­tal rev­enue...

GSK has shared de­tailed re­sults from a pair of late-stage tri­als test­ing a chron­ic he­pati­tis B treat­ment orig­i­nal­ly de­vel­oped by Io­n­is Phar­ma­ceu­ti­cals, with reg­u­la­to­ry re­views...

Ab­b­Vie said the FDA has ap­proved an an­ti­body-drug con­ju­gate it ob­tained as a part of its $10.1 bil­lionbuy­out of Im­muno­Gen for an ul­tra-rare but...